

Sprycel[®] (dasatinib) – First-time generic

- On September 1, 2024, <u>Apotex launched</u> an <u>AB-rated</u> generic version of Bristol Myers Squibb's <u>Sprycel (dasatinib)</u> tablets.
 - Apotex has been granted 180 days of generic exclusivity for its generic Sprycel.
- Sprycel is approved for the treatment of adult patients with:
 - Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
 - Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib
 - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
- Sprycel is also approved for the treatment of pediatric patients 1 year of age and older with:
 - Ph+ CML in chronic phase
 - Newly diagnosed Ph+ ALL in combination with chemotherapy.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.